The
CDH1 gene (OMIM:192090) encodes the protein E-cadherin, a cell-to-cell adhesion molecule.
1 Hereditary diffuse gastric cancer (HDGC) syndrome is caused by germline pathogenic variants in the
CDH1 gene and is characterized by an increased risk for diffuse gastric cancer (DGC) and lobular breast cancer (LBC).
2 Clinical testing criteria and medical management recommendations for HDGC were first established and published in 1999 by the International Gastric Cancer Linkage Consortium (IGCLC), a multidisciplinary collaboration of international clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists.
3 Revisions to the initial criteria were subsequently published in 2010 and 2015 (Table 1).
2,4 Recent evaluation of the revised 2015 IGCLC clinical testing criteria in a laboratory-based
CDH1 pathogenic variant cohort found that 65% of all individuals with pathogenic variants did not meet criteria.
5 In addition, it has been suggested that
CDH1 pathogenic variants may be present in women presenting with lobular breast cancer and no family history of gastric cancer.
6,7 International Gastric Cancer Linkage Consortium criteria were developed to define a clinical syndrome and facilitate identification of risk genes rather than to determine risk in all individuals with a genetically defined syndrome. These observations suggest that criteria for clinical HDGC and genetic
CDH1 syndromes may need to be separated.